Eyenovia and EVERSANA Announce Partnership to Support the Potential Launch and Commercialization of MydCombi™ for Mydriasis
News Release
View printer-friendly version << Back
Eyenovia and EVERSANA Announce Partnership to Support the Potential Launch and Commercialization of MydCombi™ for Mydriasis
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210323005351/en/
This announcement follows the
If MydCombi is approved, EVERSANA will serve as Eyenovia’s exclusive distributor for all customers in
“Eyenovia is striving to make the MydCombi launch efficient and seamless for its eye care provider customers,” said
MydCombi was developed to address several challenges eye care practitioners and their patients face related to pupil dilation. The current standard of care for pupil dilation requires multiple eye drops including a topical anesthetic, given at least several minutes apart, which can take considerable time and often cause both discomfort and drug overflow. The design of eyedroppers also lends itself to the possibility of inadvertent contact with the eye itself, which may be an issue, as the same eyedropper bottle is often shared among a number of patients. In contrast, MydCombi is delivered by Eyenovia’s proprietary Optejet dispenser, designed to ensure consistent and easy application of two mydriatic medications in a quick, touchless micro-mist application. The product is designed with no protruding parts, which may help prevent accidental touching of the ocular surface.
“We believe in MydCombi’s potential to provide patients clinical benefits and a more comfortable experience during eye exams,” said
About
About EVERSANA
EVERSANA™ is the leading provider of global services to the life sciences industry. The company’s integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners and payers. The company serves more than 500 organizations, including innovative start-ups and established pharmaceutical companies, to advance life science solutions for a healthier world.
Except for historical information, all of the statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions, including estimated market opportunities for our product candidates and platform technology. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20210323005351/en/
Eyenovia Contact:
Chief Financial Officer,
jgandolfo@eyenovia.com
EVERSANA Contact:
Chief Marketing and Corporate Communications Officer, EVERSANA
sarah.zwicky@eversana.com
(414) 434-4691
Eyenovia Investor Contact:
eric@lifesciadvisors.com
(646) 751-4363
Eyenovia Media Contact:
schoinksi@pazangahealth.com
(860) 301-5058
Source: